Browsing: Mahzi

Conditions

Mahzi Therapeutics Announces FDA Rare Pediatric Disease Designation for MZ-1866 Investigational Therapy for Pitt Hopkins Syndrome

By 0

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 /PRNewswire/ — Mahzi Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to MZ-1866, Mahzi’s investigational gene therapy for the treatment of Pitt Hopkins syndrome. The designation was…